India's Glenmark Pharma falls after agreeing to $29.6 million settlement in US
17/07/2026 09:26
BUZZ-India's Glenmark Pharma falls after agreeing to $29.6 million settlement in US ** Shares of Glenmark Pharmaceuticals GLEN.NS fall as much as 2.5% to 2,229 rupees; set for the third session of losses
** A coalition of 48 states and territories in the United States reached a $29.6 million settlement with GLEN and will make installment payments through 2030
** They accuse the co of helping inflate prices of generic drugs and limiting competition
** GLEN denied wrongdoing but agreed to cooperate with ongoing state lawsuits and make changes to ensure compliance with antitrust law
** Ten analysts have a "Buy" rating on average; median PT is 2,575 rupees - data compiled by LSEG
** YTD, GLEN up 10.5%
(Reporting by Urvi Dugar in Bengaluru)
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter